View Older Stories
-
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
-
CASI Pharmaceuticals gets Nasdaq extension until February 17, 2026
-
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
-
CASI Pharmaceuticals secures up to $20 million convertible note financing
-
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing
-
CASI Pharmaceuticals reports phase 1 results for CID-103 in blood disorder
-
CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting
-
CASI Pharmaceuticals Announces Changes in Board Governance
-
CASI Pharma (CASI) Misses Q3 EPS by 67c
-
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
-
CASI Pharmaceuticals appeals NASDAQ delisting determination
-
CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
-
CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
-
CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting
-
CASI Pharmaceuticals adds James Huang to board of directors
-
CASI Pharmaceuticals Appoints James Huang to Board of Directors
-
CASI Pharmaceuticals receives clearance to escalate CID-103 dose in ITP trial
-
CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study
-
CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
-
CASI Pharmaceuticals adds biotech veteran to board
-
CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors
-
CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results
-
CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025
-
CASI Pharmaceuticals receives FDA clearance for CID-103 kidney transplant study
-
CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)
-
CASI Pharmaceuticals names David Cory as new CEO
-
CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program
-
CASI Pharmaceuticals Provides Business and Clinical Update
-
CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results
-
CASI Pharma (CASI) to Divest Assets in China
-
CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China
-
CASI Pharma (CASI) Receives Nasdaq Non-compliance Notice
-
CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement
-
CASI Pharma (CASI) receives non-binding proposal to acquire entire china business
-
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company
-
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results
-
CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia
-
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
-
CASI Pharma (CASI) Receives CTA Approval From China's NMPA for CID-103
-
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
-
CASI Pharma (CASI) Reports Q2 Loss of $0.52
-
CASI Pharmaceuticals (CASI) announces appointment of Daniel Lang, MD as CFO and SVP
-
After-hours movers: Micron Technology, Levi, AeroVironment, and more
-
CASI Pharma (CASI) To Submit IND Application For CID-103, Announces Receipt of Non-Binding Proposal to Acquire Entire China Business
-
CASI Pharma (CASI) Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He
